UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission File Number: 002-023311

ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of registrant's name into English)

68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On March 12, 2025, Ascentage Pharma Group International (“Ascentage”) issued a press release entitled “ASCENTAGE PHARMA TO REPORT FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON MARCH 27, 2025”.

A copy of the press release is attached as Exhibit 99.1 to this Form 6-K and is incorporated by reference herein

INDEX TO EXHIBITS

Exhibit Number	Exhibit Title
99.1	Press Release, dated March 12, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
	(Registrant)
Date: March 12, 2025	/s/ Dajun Yang
	Dajun Yang
	Chief Executive Officer